Our recent research on HCC resistance demonstrated that activation of the enzyme AMP‐activated kinase (AMPK) inhibits the PI3K/Akt pathway and sensitizes HCC cells to sorafenib (Bort et al., 2017). Here, AKT1 is linked to hepatocellular carcinoma.